Adage Capital Partners’s NewAmsterdam Pharma NAMS Stock Holding History

Adage Capital Partners’s Portfolio NAMS Stock Details NAMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$18.6M	Sell	550,000 -556,631	-50%	-$18.3M	0.03%	514
2026 Q1	$35.4M	Sell	1,106,631 -300,000	-21%	-$9.77M	0.05%	323
2025 Q4	$49.3M	Sell	1,406,631 -1,170,000	-45%	-$42.6M	0.07%	259
2025 Q3	$73.3M	Sell	2,576,631 -436,378	-14%	-$10.5M	0.12%	169
2025 Q2	$54.6M	Buy	3,013,009 +1,062,359	+54%	+$19.4M	0.09%	219
2025 Q1	$39.9M	Buy	1,950,650 +900,650	+86%	+$20M	0.07%	270
2024 Q4	$27M	Sell	1,050,000 -330,000	-24%	-$7.01M	0.05%	359
2024 Q3	$22.9M	Sell	1,380,000 -150,000	-10%	-$2.6M	0.04%	421
2024 Q2	$29.4M	Sell	1,530,000 -294,601	-16%	-$5.91M	0.05%	341
2024 Q1	$43.2M	Buy	1,824,601 +524,601	+40%	+$10.6M	0.08%	257
2023 Q4	$14.5M	Buy	1,300,000 +100,000	+8%	+$916K	0.03%	516
2023 Q3	$11.1M	Hold	1,200,000	–	–	0.03%	539
2023 Q2	$14.3M	Buy	+1,200,000	New	+$15.9M	0.03%	494

Other funds holding NAMS

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

DFO

Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

Adage Capital Partners's NAMS Position: Q2 2026 in Review

Adage Capital Partners reduced its NewAmsterdam Pharma (NAMS) stake by 50% in Q2 2026, selling an estimated $18.3M and leaving 550,000 shares worth $18.6M. The position accounts for 0.03% of the portfolio, ranked #514.

Adage Capital Partners first reported a position in NAMS in Q2 2023 and has held it in 13 quarters since. The position peaked at $73.3M in Q3 2025. 195 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

Adage Capital Partners held 550,000 shares of NewAmsterdam Pharma worth $18.6M as of Q2 2026.
Adage Capital Partners sold 556,631 NewAmsterdam Pharma shares in Q2 2026, an estimated $18.3M.
NewAmsterdam Pharma made up 0.03% of Adage Capital Partners's portfolio in Q2 2026, its #514 holding.
Adage Capital Partners first reported a position in NewAmsterdam Pharma in Q2 2023 and has held it in 13 quarters since.
Adage Capital Partners's NewAmsterdam Pharma position peaked at $73.3M in Q3 2025.
195 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on Adage Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.